الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 165 |  |  |
| | | from | 165 | | |
Abstract
Background
There are insufficient direct comparative studies addressing the impact of the type of statin on their respective efficacy in heart failure (HF). The aim of the current study was to compare the effects of lipophilic (atorvastatin) versus hydrophilic (rosuvastatin) on left ventricular function, inflammatory and fibrosis biomarkers in patients with chronic HF.
Methods
This was a prospective, randomized, comparative, parallel study. A total of 85 patients with chronic HF optimized on guideline directed therapy were randomized to receive either atorvastatin 40 mg (n=42) or rosuvastatin 20 mg (n=43) for 6 months. Baseline and follow-up assessment included 2D echocardiography, measurement of N-terminal pro-brain natriuretic peptide (NT pro-BNP), interleukin-6 (IL-6), and soluble suppression of tumorigenicity 2 (sST2) levels, liver enzymes and lipid profile.
Results
The increase in left ventricular ejection fraction (LVEF) was significantly higher in the atorvastatin group compared to the rosuvastatin group (20.42% [8.76-36.57] vs 10.26% [5.26-15.38], p=0.001). The reduction in left ventricular end diastolic and end systolic volume was comparable between the 2 groups. The decrease in sST2 levels was significantly higher in the atorvastatin compared to the rosuvastatin group (-44.5% [-65.85 to -22.7] vs -25.1% [-46.55 to -14.09], p= 0.004). There was a significant reduction in NT-pro BNP and IL-6 levels in both groups, yet the reduction was comparable in both groups.
Conclusion
The study results suggest that lipophilic atorvastatin is superior to hydrophilic rosuvastatin in increasing LVEF and reducing fibrosis marker sST2 in heart failure patients.
Trial registration ID: NCT03255044, registered on 21/8/2017